The EIC Accelerator is the European Innovation Council's flagship instrument for single-company, high-potential deep-tech innovation — and historically the largest non-dilutive grant programme available to European MedTech startups. Winning an application is not a matter of writing polish. It is a matter of bringing a defensible innovation claim, a credible go-to-market plan, a regulatory plan that a panel of MedTech reviewers will not shred, and a founding team the evaluators believe can actually execute. At the general framing level — because specific terms, budgets, cut-off dates, and evaluation criteria move from one work programme to the next — the winning pattern across successful MedTech applicants is the same: precise innovation story, honest regulatory path, real commercial traction or the credible route to it, and a team the panel trusts.

By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.

TL;DR

  • The EIC Accelerator is the European Innovation Council's single-company instrument for high-potential deep-tech and deep-science innovation, historically combining grant funding with an equity-style investment component.
  • It is the largest non-dilutive grant programme an individual MedTech startup can realistically target at the EU level — and the most competitive.
  • Specific terms (budget per project, cut-off dates, grant-to-equity ratio, eligibility thresholds, evaluation criteria) change from one work programme to the next. Every figure in this post is framed at general level for orientation. Verify current terms directly at the European Innovation Council portal before any number enters a plan.
  • The winning pattern across successful MedTech applications is consistent: a sharp innovation claim, a realistic MDR regulatory plan, a commercial story grounded in evidence, and a team the panel trusts to execute.
  • The regulatory dimension of the application is where most MedTech submissions quietly fail. Panels include MedTech reviewers who have seen the difference between a real regulatory plan and a plausible-sounding one.
  • Every euro of EIC Accelerator funding is still subject to the full MDR obligations under Regulation (EU) 2017/745, Article 10. Winning the grant does not reduce the certification work — it finances it.

Why the EIC Accelerator matters for MedTech founders

For a European MedTech startup facing the long pre-revenue runway that MDR imposes, the EIC Accelerator is the single most visible non-dilutive instrument at EU level. The reasons are structural. The ticket sizes are large enough to move the needle on a regulated project. The programme is open to single companies, not consortia. And the validation signal that comes with a successful award carries weight in subsequent investor conversations that very few other signals can match.

None of this makes the programme easy to win. The application process is substantive, the evaluation panels are experienced, the cut-off rates are high, and the work of putting a credible submission together takes months of concentrated founder time. Founders who treat the EIC Accelerator as a lottery ticket — writing a rushed application the week before the deadline and hoping for the best — lose that time with nothing to show for it. Founders who treat it as a serious commercial exercise, prepared over months, have a realistic shot.

This post is the general-framing walk-through of what a winning EIC Accelerator application looks like for a MedTech startup. The specific numbers, dates, and evaluation weights move between work programmes — this post stays at the level of the pattern that persists across them, so the advice stays useful even as the specific terms evolve. For the broader non-dilutive landscape this programme sits inside, the parent post is non-dilutive funding for MedTech startups.

What the EIC Accelerator is at general framing

The EIC Accelerator is the European Innovation Council's flagship single-company instrument. It is designed to support high-potential, deep-tech and deep-science innovation at the stage where the innovation is past the pure research phase and moving toward market entry, but where commercial investors alone are unlikely to finance the full path — typically because the technical risk is still high, the regulatory path is long, or the market-making effort is substantial.

At general framing, the programme has historically offered two components bundled together. The first is a grant component for innovation activities — the work of taking a proven concept through the development, validation, and regulatory milestones that precede first commercial revenue. The second is an equity-style investment component, offered alongside the grant, that the company may or may not accept depending on its situation and preferences. The combination — grant plus optional equity — is unusual at the public-funding level and is one of the defining features of the instrument.

Selection is competitive. The process typically runs in stages — an initial short application, a longer full proposal, and a final interview round in front of a panel of evaluators — with attrition at each stage. The evaluators are experienced practitioners drawn from industry, investment, and domain expertise, including MedTech specialists for MedTech submissions. The cut-off rates are high enough that a rushed application effectively has no chance.

Every specific figure that matters for a working application — the maximum grant amount, the maximum equity investment, the cut-off dates, the eligibility thresholds, the exact evaluation weights — is defined in the current work programme and changes as the programme cycles. Before any number in a business plan or board document is attributed to the EIC Accelerator, verify the live figures directly at the European Innovation Council portal. Treat anything in this post as pattern, not promise.

What the EIC Accelerator funds for MedTech

At general framing, the instrument funds the innovation activities that sit between proven technology and first commercial revenue. For a MedTech startup, this typically includes prototype refinement toward a final design, pre-clinical and clinical validation work, the core technical file and QMS work needed for MDR conformity, pilot deployments in clinical or operational settings, and the early go-to-market activities that prepare for commercial launch.

What the programme has historically not funded — or has funded only as a small accessory to the core innovation work — is pure basic research upstream of a validated concept, and pure commercial scale-up downstream of an achieved market entry. The first belongs in research framework programmes like Horizon Europe consortia. The second belongs in commercial debt or equity. The EIC Accelerator sits in between.

For MedTech specifically, the instrument is valuable for projects where the innovation is genuine deep technology or deep science, where the regulatory path is a meaningful component of the total cost, and where the team has a credible plan to reach market entry but needs capital that commercial investors alone would not underwrite at acceptable terms. Projects that do not fit any of those criteria — a me-too device, a marginal improvement, or a pure software play with no defensible technical innovation — are unlikely to survive the evaluation regardless of how well the application is written.

The application sections at general level

The application structure has varied across work programmes, but the underlying questions the evaluators want answered have been consistent. At general level, every successful MedTech submission answers the same core set of questions clearly.

The innovation. What is the actual technical or scientific step-change that this project represents, and why is it defensible? This is not "we are building a medical device." It is the specific novelty — the measurement technique, the algorithm, the material, the mechanism, the device architecture — that distinguishes the project from what exists. Evaluators read hundreds of applications that fail this test because the applicant cannot articulate what the innovation actually is in one tight paragraph.

The market and impact. Who is the user, who is the buyer, what problem does the device solve, and what is the evidence that the market exists and that the proposed product actually addresses it? MedTech panels have seen every variant of the top-down market-size argument and will weight bottom-up evidence much more heavily — conversations with clinicians, letters of intent from hospital procurement, pilot agreements, early revenue if any.

The go-to-market plan. How does the company get from the current state to commercial revenue, on what timeline, through which channels, with what pricing and reimbursement logic? This is where MedTech-specific realities show up — the reimbursement pathway, the public or private payer structure, the procurement cycle in the target markets, the clinical evidence required to support adoption.

The regulatory plan. The section where most MedTech applications quietly fail. Covered in its own section below.

The team. Who is executing this, what is their track record, and what is the evidence they can actually deliver on the plan they are describing? Evaluators look for founder commitment, complementary skills, domain experience, and honest acknowledgement of gaps.

The financial plan and request. What is the total cost of the project, what is the requested grant and optional equity, how do the requested funds map to specific work packages, and what is the co-financing or matching capital story where relevant?

Each of these sections has to be internally consistent with the others. A common failure mode is an application where the innovation story, the regulatory plan, the go-to-market plan, and the financial model have been written by different hands and never reconciled. The evaluators spot this immediately.

The regulatory dimension of the application

This is where Tibor's perspective from the Notified Body side matters most. MedTech applications to the EIC Accelerator are evaluated by panels that include people who have seen MDR certification files. They can tell the difference between a regulatory plan that reflects a real understanding of the pathway and a regulatory plan that was written by someone who has never walked a device through the process.

A credible MedTech regulatory plan for the EIC Accelerator states the device's intended purpose precisely, identifies the risk class with the specific MDR classification rule from Annex VIII, names the conformity assessment route, describes the clinical evidence strategy honestly (literature, equivalence, or new clinical investigation and why), maps the work to be funded by the grant to the technical file sections it produces, and acknowledges the Notified Body capacity constraint as a real timeline factor rather than a footnote.

An application that says "we will obtain CE marking under MDR within the project duration" without any of that detail is not a regulatory plan. It is a placeholder, and the evaluators read it as one. An application that names the class, names the rule, names the route, describes the evidence pathway in plain terms, and budgets the regulatory work against specific milestones is taken seriously even when the panel disagrees with some of the choices.

Every euro the EIC Accelerator could award is still subject to the full obligations of Regulation (EU) 2017/745, Article 10, on the manufacturer. The grant finances the work; it does not replace the work. Applications that implicitly treat the grant as a substitute for doing the regulatory work properly get caught at the panel stage.

The pitch reality

For MedTech applications that reach the interview round, the pitch is typically to a panel that combines investors, domain experts, and specialists — including, for MedTech submissions, people who know the regulatory path intimately. The questions are direct. The panel has read the application. They are not looking for a rehearsal of the written document. They are looking for confidence, command of the specifics, honesty about the gaps, and a sense that the team in the room is the team that can actually execute.

The pattern across successful MedTech pitches we have seen is the same. The founder speaks plainly about the innovation and can defend the novelty under pressure. The founder knows the intended purpose, the risk class, and the clinical evidence pathway without consulting notes. The founder can describe the go-to-market plan in terms the panel recognises — real payers, real procurement cycles, real clinical champions. The founder acknowledges the risks honestly rather than papering over them.

The failure pattern is also consistent. Over-rehearsed answers that break the moment a panel member asks a follow-up question the founder was not expecting. Confidence about market size not matched by specific evidence. Vague regulatory answers that dissolve under MedTech-specific questioning. A team that clearly does not have the complementary skills the project requires, presented as if it did.

The pitch is not where an application is won from a losing position. It is where an application that is already strong on paper either confirms its strength in person or does not. Founders who have done the work in advance — who can speak about their own submission without reading it — tend to confirm the strength. Founders who are reading their own deck out loud tend to lose it in the room.

Common mistakes MedTech applicants make

Four patterns repeat across the MedTech EIC Accelerator applications we have watched fail.

Writing a generic innovation story. "We are building an innovative medical device using AI" is not an innovation story. It is a tagline. The innovation story has to name the specific technical or scientific step-change, explain why it is defensible, and show why a generalist reviewer outside the exact domain can understand the novelty in one read.

Treating the regulatory section as paperwork. The regulatory section is load-bearing for MedTech applications. An application that cannot state the class, the rule, the conformity assessment route, and the clinical evidence strategy with confidence is telling the panel the team has not seriously engaged with the regulatory reality yet.

Overstating the market and understating the risks. Panels have seen every top-down TAM calculation. They read honest risk acknowledgement as a strength signal, not a weakness. Applications that claim everything is on track and every risk is mitigated read as naive at best and dishonest at worst.

Rushing the application. A serious EIC Accelerator submission is not a week of work. It is months of preparation, iteration, and honest pressure-testing — ideally with someone outside the founding team who has read successful applications before. Founders who start the application a few weeks before the cut-off almost never clear the first stage.

The Subtract to Ship angle on EIC Accelerator applications

The Subtract to Ship framework applied to EIC Accelerator applications is not "apply to everything." It is "prepare one strong application well, or do not apply at all." The calendar cost of a serious submission is large enough that half-preparing two applications is worse than fully preparing one.

The subtraction discipline inside the application itself is about cutting every sentence that does not do real work. Generic framing of the regulatory environment, generic market context, generic claims about importance of innovation in healthcare — all of it costs word budget and adds nothing. What survives the subtraction is the specific: the specific innovation, the specific device, the specific intended purpose and class, the specific clinical evidence pathway, the specific commercial plan, the specific team, the specific milestones the grant would fund.

The test inside the application is the same test the framework applies everywhere. Does this sentence, this figure, this claim trace to something the panel needs to know to evaluate the project? If yes, keep it. If no, cut it. The word budget is limited in every work programme the EIC Accelerator has ever run, and evaluators read faster than applicants believe. The application that reads cleanly, answers the panel's questions directly, and wastes none of the space has a real advantage over one that meanders.

Reality Check — Where do you stand?

  1. Can you state the specific technical or scientific innovation at the core of your project in one paragraph, without hand-waving?
  2. Do you know the intended purpose, risk class, classification rule, and conformity assessment route for your device, and can you defend each of those in front of a MedTech-literate panel?
  3. Is your clinical evidence strategy realistic — specifically, does it name literature, equivalence, or new clinical investigation and explain the choice?
  4. Is your go-to-market plan grounded in evidence from real conversations with clinicians, payers, or procurement — or is it a top-down market-size argument?
  5. Does your financial model map requested funds to specific work packages, and does each work package produce a deliverable an evaluator can recognise?
  6. Has someone outside your founding team — ideally someone who has read successful EIC Accelerator applications — pressure-tested your submission before the cut-off?
  7. If you do not win this round, is the work you will have done on the application still useful for the company — or is it time you will regret spending?

Frequently Asked Questions

What is the EIC Accelerator? The EIC Accelerator is the European Innovation Council's flagship single-company instrument for high-potential deep-tech and deep-science innovation. At general framing, it has historically combined grant funding for innovation activities with an equity-style investment component offered alongside the grant. Specific terms — maximum amounts, eligibility thresholds, cut-off dates, evaluation criteria — change from one work programme to the next and must be verified at the European Innovation Council portal before relying on any figure.

Is the EIC Accelerator suitable for a MedTech startup? Yes, in principle — it has historically been one of the largest non-dilutive sources of capital available to single European MedTech companies. The programme is well suited to projects where the innovation is genuine deep technology or deep science, where the regulatory path is a meaningful cost component, and where the team has a credible route to market but needs capital that commercial investors alone would not underwrite at acceptable terms. Me-too devices and marginal improvements rarely succeed.

How hard is it to win an EIC Accelerator grant? Very competitive. Cut-off rates across stages are high, the application process is substantive, and the evaluation panels are experienced. A serious submission requires months of preparation rather than weeks. Founders who treat the programme as a lottery ticket usually get nothing for the time spent.

How long does the EIC Accelerator application process take? Plan months, not weeks, for the preparation, and additional months for the multi-stage evaluation — short application, full proposal, interview round — with attrition at each stage. From the decision to apply to a final funding decision, the total cycle is long enough that founders in a cash crisis cannot rely on it as their primary funding plan. It is a strategic instrument, not a rescue.

Does winning an EIC Accelerator grant reduce the MDR work for my device? No. Every obligation under Regulation (EU) 2017/745, Article 10, continues to apply regardless of the funding source. The grant finances the regulatory work; it does not replace it. Treating the grant as a substitute for doing the MDR work properly is one of the signals evaluators catch at the panel stage.

Can I apply to the EIC Accelerator and raise venture capital at the same time? In many cases yes — the two are frequently compatible, and the EIC Accelerator has historically included an equity-style component that can sit alongside private investors. The specific rules on stacking and timing change between work programmes, so verify the current conditions at the European Innovation Council portal before structuring a combined round.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Article 10 (manufacturer obligations). Official Journal L 117, 5.5.2017.
  2. European Innovation Council — EIC Accelerator programme information. https://eic.ec.europa.eu — verify current programme terms, open cut-off dates, eligibility thresholds, and evaluation criteria directly with the Commission before relying on specific figures.
  3. European Innovation Council Work Programme — current version. Verify the live work programme document at the European Innovation Council portal before any figure from this post enters a funding plan, business plan, or board document.

Note on current-terms verification: Every reference to the EIC Accelerator in this post is framed at general level and reflects the pattern of the programme as it has historically operated. Maximum grant amounts, equity ticket sizes, cut-off dates, eligibility thresholds, evaluation weights, and the precise structure of the application stages are defined in the current work programme and change between cycles. Before any specific figure or process detail from this post enters a funding plan, pitch deck, or board document, confirm the current terms directly at the European Innovation Council portal. This is a working rule, not a disclaimer.

This post is part of the Funding, Business Models & Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. The EIC Accelerator is the most visible single-company non-dilutive instrument at EU level, and preparing a serious application is a months-long exercise in which the specific shape of your device, your regulatory path, and your commercial plan determines whether the submission lands — when the work of turning a strong project into a panel-ready application exceeds what a blog post can cover, a sparring partner who has walked founders through the preparation is the shortest path to a submission the evaluators take seriously.